All In Biotech

Drug Trial Radar · NCT07011797

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Jun 17, 2025

Primary completion

Mar 23, 2026

Study completion Apr 9, 2026

Sponsor

Lead sponsor
Corxel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.

Conditions

  • Obesity

Interventions

  • CX11Drug

    CX11 tablets administered orally once daily (QD) with meals

  • PlaceboOther

    Matching placebo tablets administered orally once daily (QD) with meals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight from baselineTime frame: At Week 26

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central

    Phoenix, Arizona

  • 310 Clinical Research - Alliance Clinical - Los Angeles

    Inglewood, California

  • Acclaim Clinical Research - Alliance Clinical - San Diego

    San Diego, California

  • Angels Clinical Research Institute - Miami

    Doral, Florida

  • AES - DRS - Optimal Research Florida - Melbourne

    Melbourne, Florida

  • Angels Clinical Research Institute

    Miami, Florida

  • Palm Springs Community Health Center

    Miami Lakes, Florida

  • Oceanic Research Group, LLC

    North Miami Beach, Florida

  • Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS

    Savannah, Georgia

  • Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS

    Thomasville, Georgia

  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS

    Valparaiso, Indiana

  • Mankato Clinic - East Main Street - Javara - PPDS

    Mankato, Minnesota

  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS

    Cincinnati, Ohio

  • Velocity Clinical Research - Dallas - PPDS

    Dallas, Texas

  • Epic Clinical Research - Alliance Clinical - Lewisville

    Lewisville, Texas

  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio

    San Antonio, Texas

  • Flourish Research - San Antonio - PPDS

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.